PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents growing 13.37% while AGEN's declined -38.39%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of AGEN's -38.39%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of AGEN's -31.56%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Below half AGEN's 0.42%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of AGEN's 0.19%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of AGEN's -18.14%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Above 1.5x AGEN's -1.61%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
2.29%
Less than half of AGEN's -42.72%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Below half of AGEN's 23.34%. Michael Burry suspects a big gap in pre-sales traction.
-2.29%
Less than half of AGEN's 40.88%. David Dodd sees fewer expansions in other current obligations.
-6.99%
Less than half of AGEN's 21.95%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Above 1.5x AGEN's -5.16%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Less than half of AGEN's 3.51%. David Dodd sees far fewer liability expansions relative to competitor.
10.53%
Above 1.5x AGEN's 3.40%. Michael Burry suspects heavy new equity expansion or dilution.
-2.12%
Below half AGEN's -5.48%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.96%
Less than half of AGEN's 125.95%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half AGEN's -30.30%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half AGEN's -18.14%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Above 1.5x AGEN's -1.34%. Michael Burry sees a major jump. Investigate leverage rationale.
-13.63%
Less than half of AGEN's 72.97%. David Dodd sees better deleveraging or stronger cash buildup than competitor.